DE69433133D1 - Lösliches thrombomodulin enthaltende zubereitung - Google Patents

Lösliches thrombomodulin enthaltende zubereitung

Info

Publication number
DE69433133D1
DE69433133D1 DE69433133T DE69433133T DE69433133D1 DE 69433133 D1 DE69433133 D1 DE 69433133D1 DE 69433133 T DE69433133 T DE 69433133T DE 69433133 T DE69433133 T DE 69433133T DE 69433133 D1 DE69433133 D1 DE 69433133D1
Authority
DE
Germany
Prior art keywords
soluble
soluble thrombomodulin
thrombomodulins
producing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433133T
Other languages
English (en)
Other versions
DE69433133T2 (de
Inventor
Yasuyuki Kunihiro
Ryo Tanaka
Seishichi Hata
Shigeharu Suzuki
Yumio Kudoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of DE69433133D1 publication Critical patent/DE69433133D1/de
Application granted granted Critical
Publication of DE69433133T2 publication Critical patent/DE69433133T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Seasonings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69433133T 1993-12-17 1994-12-16 Lösliches thrombomodulin enthaltende zubereitung Expired - Lifetime DE69433133T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31840593 1993-12-17
JP31840593 1993-12-17
PCT/JP1994/002128 WO1995016460A1 (fr) 1993-12-17 1994-12-16 Dispositif a semi-conducteur

Publications (2)

Publication Number Publication Date
DE69433133D1 true DE69433133D1 (de) 2003-10-16
DE69433133T2 DE69433133T2 (de) 2004-04-01

Family

ID=18098790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433133T Expired - Lifetime DE69433133T2 (de) 1993-12-17 1994-12-16 Lösliches thrombomodulin enthaltende zubereitung

Country Status (8)

Country Link
US (1) US5834028A (de)
EP (1) EP0689843B1 (de)
JP (1) JP3537440B2 (de)
AT (1) ATE249234T1 (de)
AU (1) AU692497B2 (de)
CA (1) CA2156255C (de)
DE (1) DE69433133T2 (de)
WO (1) WO1995016460A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JP4460762B2 (ja) 1997-10-15 2010-05-12 旭化成ファーマ株式会社 トロンボモジュリン水溶液注射剤の貯蔵・流通時の品質保持方法
PT1051155E (pt) * 1998-01-30 2002-10-31 Novartis Consumer Health Sa Solucoes nasais
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
AU2006200638B2 (en) * 1999-10-01 2007-11-01 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
AU2004201694B2 (en) * 1999-10-01 2006-03-02 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
WO2003061687A1 (en) * 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
WO2004028557A1 (ja) * 2002-09-26 2004-04-08 Shionogi & Co., Ltd. 安定化されたタンパク組成物
WO2005000096A2 (en) * 2003-06-05 2005-01-06 Hydrocision, Inc. Disposable endoscope and method of making a disposable endoscope
US7833978B2 (en) 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP1910844B1 (de) 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta-struktur-bindende verbindungen
EP1907864A2 (de) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Verfahren zur bestimmung der auswirkung einer behandlung auf den cross-beta struktur-gehalt eines proteins; auswahl von behandlungen und verwendungen davon
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
ES2360610T3 (es) * 2005-10-13 2011-06-07 Eli Lilly And Company Tratamiento de la insuficiencia renal aguda con trombomodulina soluble.
EP2007800A1 (de) * 2006-03-17 2008-12-31 Crossbeta Biosciences B.V. Verfahren zur bindung von kreuz-beta-strukturen durch chaperone
AU2008230465B2 (en) 2007-03-23 2011-10-13 Asahi Kasei Pharma Corporation Method for producing high-purity soluble thrombomodulin
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
CN102216326A (zh) * 2008-11-12 2011-10-12 伊莱利利公司 凝血调节蛋白变体的组合物和使用方法
EP3150628A1 (de) * 2010-04-30 2017-04-05 Asahi Kasei Pharma Corporation Hochreines lösliches thrombomodulin
JP6541581B2 (ja) * 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 低濃度抗体製剤
CN107987157A (zh) * 2017-12-19 2018-05-04 江苏艾迪药业有限公司 一种可工业化生产的人来源血凝调节蛋白的制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 Ｎ－ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3856335T2 (de) * 1987-01-08 2000-01-27 Asahi Chemical Ind Peptid zur beschleunigung der wirkung des proteins-c mit thrombin
JP2738428B2 (ja) * 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
JPS6440433A (en) * 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
US5202421A (en) * 1988-12-27 1993-04-13 Mochida Pharmaceutical Co., Ltd. Anticoagulant substance obtained from urine and process for the preparation thereof
JPH0798840B2 (ja) * 1988-12-27 1995-10-25 持田製薬株式会社 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物
JPH02255699A (ja) * 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
CA2042399A1 (en) * 1989-09-25 1991-03-26 Shuji Yamamoto Isolated physiologically active human thrombomodulin polypeptide
IT1240314B (it) * 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0489180A4 (en) * 1990-06-27 1993-03-31 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JP3376591B2 (ja) * 1991-08-28 2003-02-10 三菱ウェルファーマ株式会社 プロテインｃ活性化促進剤
ATE264913T1 (de) * 1992-02-05 2004-05-15 Paion Gmbh Protease-resistente analoge des thrombomodulin
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法

Also Published As

Publication number Publication date
AU692497B2 (en) 1998-06-11
EP0689843A1 (de) 1996-01-03
CA2156255C (en) 2008-02-05
ATE249234T1 (de) 2003-09-15
CA2156255A1 (en) 1995-06-22
EP0689843A4 (de) 2000-06-28
US5834028A (en) 1998-11-10
EP0689843B1 (de) 2003-09-10
AU1200995A (en) 1995-07-03
DE69433133T2 (de) 2004-04-01
WO1995016460A1 (fr) 1995-06-22
JP3537440B2 (ja) 2004-06-14

Similar Documents

Publication Publication Date Title
DE69433133D1 (de) Lösliches thrombomodulin enthaltende zubereitung
CA2070254A1 (en) Thrombin inhibitors
AU3496297A (en) Anticoagulant agents
TW225532B (de)
EP1964569A3 (de) 3'- oder 2'-Hydroxymethyl-substituierte Nukleosidderivate zur Behandlung von Virusinfektionen
AU6549394A (en) Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
AU5242000A (en) Nematicidal trifluorobutenes
LTIP862A (en) Method for preparing amino acid derivatives and pharmaceuthical compositions thereof
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
ATE163645T1 (de) Eintopfverfahren zur herstellung von 3- chinoloncarbonsäurederivaten
FI942625A0 (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
AU667530B2 (en) Removal of antibodies from blood-derived compositions while retaining coagulation factors
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
CA2299421A1 (en) A universally applicable blood plasma
NO177312C (no) Fremgangsmåte for fremstilling av hirudinderivater med forsinket virkning
AU8003094A (en) Method of stabilizing protein c or activated protein c and stabilized composition
CA2037002A1 (en) Ethylene/pentene-1 copolymer, process for the preparation of the same, and ethylene/pentene-1 copolymer composition
CA1340236C (en) Method of preparing highly purified alpha-1-proteinage inhibitor
NO911237D0 (no) Fremgangsmaate for fremstilling av hydroxymethyl-indolizidiner og -kinolizidiner.
DE60004457D1 (de) Verfahren zur Verlängerung der Haltbarkeit von Schnittblumen
DE59807906D1 (de) Verfahren zur Herstellung von bissfesten Früchten
JPH0753403A (ja) ウロキナーゼ前駆体の加熱処理方法
RU93055683A (ru) Ингибиторы вич-протеазы, способ их получения, их использование, композиция
PL332319A1 (en) Substitution bezocycloheptapyridine derivatives useful in inhibiting protweinous farnesil transferase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASAHI KASEI PHARMA CORP., TOKIO/TOKYO, JP